Cabaletta Bio Inc. (CABA)
1.80
-0.01 (-0.55%)
At close: Feb 28, 2025, 3:59 PM
1.91
5.82%
After-hours: Feb 28, 2025, 05:16 PM EST
No 1D chart data available
| Bid | 1.82 |
| Market Cap | 88.22M |
| Revenue (ttm) | 4.01M |
| Net Income (ttm) | -104.03M |
| EPS (ttm) | -2.16 |
| PE Ratio (ttm) | -0.84 |
| Forward PE | -0.93 |
| Analyst | Buy |
| Ask | 1.91 |
| Volume | 996,208 |
| Avg. Volume (20D) | 2,266,568 |
| Open | 1.82 |
| Previous Close | 1.81 |
| Day's Range | 1.71 - 1.92 |
| 52-Week Range | 1.71 - 24.67 |
| Beta | 2.47 |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART,...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 154
Stock Exchange NASDAQ
Ticker Symbol CABA
Website https://www.cabalettabio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for CABA stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 1285.04% from the latest price.
Buy 71.43%
Hold 28.57%
Sell 0.00%
3 months ago
-19.84%
Cabaletta Bio shares are trading lower after Wells...
Unlock content with
Pro Subscription
6 months ago
-34.37%
Cabaletta Bio shares are trading lower. The company reported Q2 financial results.
